Announcement of TTY Biopharm's unaudited income information in March 2023
2023.4.13
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2023/04/13 | Time of announcement | 13:33:31 |
| Subject | Announcement of TTY Biopharm's unaudited income information in March 2023 | ||||
| Date of events | 2023/04/13 | To which item it meets | paragraph 53 | ||
| Statement | 1.Date of occurrence of the event:2023/04/13 2.Company name:TTY Biopharm Co., Ltd. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office 4.Reciprocal shareholding ratios:N/A 5.Cause of occurrence:TTY Biopharm posted a consolidated net sales of $426,351 thousands (expressed in NT dollars; unaudited), a consolidated operating profit of $101,868 thousands, and a consolidated income before tax of $127,372 thousands in March 2023; net income attributed to stockholders of the company was $104,594 thousands; EPS is $0.42. Year-to-date consolidated net sales was $1,166,332 thousands (in NT dollars; unaudited), a consolidated operating profit was $245,399 thousands and consolidated income before tax was $293,342 thousands until March 2023; year-to-date net income attributed to stockholders of the company was $238,680 thousands; EPS is $0.96. 6.Countermeasures:None. 7.Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): The numbers above are unaudited. In term of the final net sales and profits, quarterly financial reports audited by independent accountants will prevail. |
||||